EDAP TMS To Participate in Major International Congresses in Japan and Germany
16 Septiembre 2004 - 9:15AM
PR Newswire (US)
EDAP TMS To Participate in Major International Congresses in Japan
and Germany VAULX-EN-VELIN, France, Sept. 16 /PRNewswire-FirstCall/
-- EDAP TMS S.A. (NASDAQ:EDAP), a global leader in the development,
marketing and distribution of a portfolio of minimally-invasive
medical devices for the treatment of urological diseases, today
announced its participation in two major upcoming international
congresses. On September 18-20, 2004, EDAP will be present at the
4th International Symposium on Therapeutic Ultrasound (ISTU) to be
held in Kyoto, Japan. This event gathers the international medical
and scientific community investigating in the development and the
use of HIFU technology to treat a wide spectrum of pathologies.
This platform will be an opportunity for EDAP to present its
successful long term HIFU clinical results obtained with
Ablatherm(R), based on the treatment of more than 5,000 patients
suffering from localized prostate cancer. It will also allow EDAP
to share its HIFU experience with other investigators and discuss
HIFU therapeutic breakthrough opportunities and investments. EDAP's
research partner INSERM, which has been actively working on HIFU
technology for years, will also be presenting its promising
development programs on therapeutic ultrasound. On September 22-25,
2004, EDAP will be participating in the 56th Congress of the German
Society for Urology (D.G.U.: Deutsche Gesellschaft f�r Urologie)
taking place in Wiesbaden, Germany. Dr. Blana and Dr. Walter, from
the Urology Department of the Regensburg's University Hospital,
will be presenting their successful clinical results at five years
using HIFU technology with Ablatherm. During the congress, specific
"Meet the Expert" meetings will be held daily on our booth (#E24)
for Urologists to discuss with clinicians about their HIFU
experience using Ablatherm on a daily practice. Germany is the 3rd
biggest world market for medical equipment and 22,000 new patients
are being diagnosed with prostate cancer every year. Approximately
2,000 HIFU treatments with the Ablatherm have already been
performed in Germany until today. Hugues de Bantel, Chief Executive
Officer of EDAP TMS, commented: "We are particularly confident in
the future growth of our Ablatherm business. The successful
introduction of mobile Ablatherm in Germany, with seven new
hospital users within the last ten months, confirms that Ablatherm
is rapidly being accepted as one of the most effective treatment
alternative for localized prostate cancer. Our participation in the
ISTU Symposium, in Kyoto, together with our long term research
partner, further illustrates that we are determined to expand HIFU
technology to other pathologies and to position the Company to meet
this next challenge". EDAP TMS S.A. is the global leader in the
development, production, marketing and distribution of a portfolio
of minimally invasive medical devices primarily for the treatment
of urological diseases. The Company currently develops and markets
devices for the minimally invasive treatment of localized prostate
cancer, using High Intensity Focused Ultrasound (HIFU), through its
EDAP SA subsidiary; it is also developing this technology for the
treatment of certain other types of tumors. EDAP TMS S.A. also
produces and commercializes medical equipment for treatment of
urinary tract stones using Extra-corporeal Shockwave Lithotripsy
(ESWL), via its TMS SA subsidiary. In addition, the Company markets
in Japan and Italy devices for the non-surgical treatment of benign
Prostate Hyperplasia (BPH) using Microwave Thermotherapy (TUMT).
For more information, contact the Investor Relations Department by
phone at +33 (0)4 78 26 40 46. For additional information on the
Company, please see the Company's web site at:
http://www.edap-tms.com/. This press release contains, in addition
to historical information, forward-looking statements that involve
risks and uncertainties. These include statements regarding the
Company's growth and expansion plans. Such statements are based on
management's current expectations and are subject to a number of
uncertainties and risks that could cause actual results to differ
materially from those described in the forward-looking statements.
Factors that may cause such a difference include, but are not
limited to, those described in the Company's filings with the
Securities and Exchange Commission. CONTACT: Hugues de Bantel -
Philippe Chauveau Blandine Confort +33-4-78-26-40-46 DATASOURCE:
EDAP TMS S.A. CONTACT: Hugues de Bantel, Philippe Chauveau or
Blandine Confort, all for EDAP TMS S.A., +33-4-78-26-40-46 Web
site: http://www.edap-tms.com/
Copyright
EDAP TMS (NASDAQ:EDAP)
Gráfica de Acción Histórica
De Ago 2024 a Sep 2024
EDAP TMS (NASDAQ:EDAP)
Gráfica de Acción Histórica
De Sep 2023 a Sep 2024